Drug intelligence / Profile preview

Orapaz

Development stage: Unknown
Lead developer: Brisk Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Topical

Overview

**Orapaz** is a prescription dental co-pack marketed by Brisk Pharmaceuticals for dental recovery and oral-care treatment support. Each kit contains cephalexin 500 mg capsules, ibuprofen 800 mg tablets, and chlorhexidine gluconate 0.12% oral rinse. The components provide antibacterial coverage, analgesic and anti-inflammatory activity, and local oral antisepsis, respectively. ([briskpharma.us](https://www.briskpharma.us/orapaz))

Brand names: Orapaz

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on Orapaz.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orapaz.

Explore the full profile